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ABSTRACT
Objective We recently demonstrated that combination
treatment with NS3 protease and NS5B polymerase
inhibitors succeeded in eradicating the virus in genotype
1b hepatitis C virus (HCV)-infected mice. In this study,
we investigated the effect of combining an NS5A
replication complex inhibitor (RCI) with either NS3
protease or NS5B inhibitors on elimination of HCV
genotypes 1b, 2a and 2b.
Design The effects of Bristol-Myers Squibb (BMS)-
605339 (NS3 protease inhibitor; PI), BMS-788329 (NS5A
RCI) and BMS-821095 (NS5B non-nucleoside analogue
inhibitor) on HCV genotypes 1b and 2a were examined
using subgenomic HCV replicon cells. HCV genotype 1b,
2a or 2b-infected human hepatocyte chimeric mice were
also treated with BMS-605339, BMS-788329 or BMS-
821095 alone or in combination with two of the drugs
for 4 weeks. Genotypic analysis of viral sequences was
achieved by direct and ultra-deep sequencing.
Results Anti-HCV effects of BMS-605339 and BMS-
821095 were more potent against genotype 1b than
against genotype 2a. In in-vivo experiments, viral
breakthrough due to the development of a high
prevalence of drug-resistant variants was observed in
mice treated with BMS-605339, BMS-788329 and BMS-
821095 in monotherapy. In contrast to monotherapy,
4 weeks of combination therapy with the NS5A RCI and
either NS3 PI or NS5B inhibitor succeeded in completely
eradicating the virus in genotype 1b HCV-infected mice.
Conversely, these combination therapies failed to
eradicate the virus in mice infected with HCV genotypes
2a or 2b.
Conclusions These oral combination therapies may
serve as a Peg-alfa-free treatment for patients chronically
infected with HCV genotype 1b.
INTRODUCTION
Hepatitis C virus (HCV) infection is a major cause
of chronic liver diseases, such as cirrhosis and
hepatocellular carcinoma.1 2 A number of new
selective inhibitors of HCV proteins, termed
direct-acting antiviral agents (DAA), are currently
under development. HCV inhibitors targeting NS3
protease and NS5A and NS5B polymerase activity
have proceeded to clinical trials for HCV-infected
patients. DAA are used in combination with
Peg-alfa and ribavirin because monotherapy with
these drugs results in the early emergence of
drug-resistant variants.3 4 As Peg-alfa/ribavirin
treatment is frequently associated with serious
adverse events, an oral Peg-alfa/ribavirin-free DAA
combination therapy would offer an ideal treat-
ment option for chronic hepatitis C patients. The
ﬁrst proof-of-concept study to combine NS3 prote-
ase and NS5B inhibitors (INFORM-1) reported
that 13 days of this combination treatment
achieved robust antiviral suppression in genotype 1
HCV-infected patients, and no evidence of resist-
ance to either compound was observed.5 Following
the INFORM-1 study, we and other groups have
also reported that a DAA-only combination com-
prising NS3 protease inhibitor (PI), Bristol-Myers
Squibb (BMS)-650032 (asunaprevir) and NS5A rep-
lication complex inhibitor (RCI), BMS-790052
(daclatasvir) can achieve high sustained virological
Signiﬁcance of this study
What is already known on this subject?
▸ Anti-HCV drug monotherapy for chronic hepatitis
C patients often results in viral breakthrough
due to the emergence of drug-resistant clones.
▸ Combination treatment of NS3 PI and NS5A
inhibitor can eradicate genotype 1b HCV in
chronic hepatitis C patients without interferon.
What are the new ﬁndings?
▸ Combination treatment of NS5A inhibitor with
either NS3 PI or NS5B inhibitor can eradicate
HCV, but the effect differs among HCV
genotypes.
How might it impact on clinical practice in
the foreseeable future?
▸ Short-term combination of NS5A inhibitor with
either NS3 PI or NS5B inhibitor might provide
an effective interferon-free treatment for geno-
type 1b chronic hepatitis C patients; however,
the combination treatment might be less effect-
ive against genotype 2.
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response (SVR) rates in patients with HCV genotype 1b infec-
tion.6 A number of DAA-only combination studies are now
entering phase 2 clinical trials.7 The effect of telaprevir was
recently analysed in genotype 2 HCV-infected patients. Fifteen
days of telaprevir monotherapy decreased the serum HCV RNA
titre by 3.7 log10 IU/ml, and 3 months of telaprevir plus
24 weeks of Peg-alfa/ribavirin triple therapy resulted in SVR in
100% of genotype 2 HCV-infected patients.8 However, the
effect of Peg-alfa/ribavirin-free DAA combination therapy on
genotype 2 HCV has not been reported.
The immunodeﬁcient urokinase-type plasminogen activator
(uPA) mouse permits repopulation of the liver with human
hepatocytes that can be infected with HCV.9 This animal
model is useful for evaluating anti-HCV drugs such as Peg-alfa
and NS3 PI.10 11 Using this animal model, we recently
described the successful elimination of HCV genotype 1b by
treatment with a combination of NS3 protease and NS5B inhi-
bitors.12 In this study, we investigated whether short-term
combination treatments with NS5A RCI and either NS3 prote-
ase or NS5B site I inhibitors could eliminate HCV in vivo in
human hepatocyte chimeric mice, and we compared the efﬁ-
cacy of the drugs against HCV genotype 1 versus genotype 2.
METHODS
Compounds and cells
BMS-605339 (NS3 PI, analogue of asunaprevir), BMS-788329
(NS5A RCI, analogue of daclatasvir) and BMS-821095 (NS5B
non-nucleoside analogue inhibitor; NNI) were synthesised by
BMS. Huh-7 cells that stably maintain HCV replicons were
propagated as subconﬂuent monolayers in Dulbecco’s modiﬁed
essential medium containing 10% fetal bovine serum, 2 mM
L-glutamine, and 0.5 mg/ml geneticin (G418; Invitrogen Corp.,
Carlsbad, California, USA) at 37°C under 5% carbon dioxide.13
Determination of IC50 in culture systems
The genotype 1b (Con 1) replicon cell line was constructed as
described previously.14 A genotype 2a ( JFH-1) cell line was gen-
erated by introducing the JFH-1 sequence from NS3 to NS5B
into the genotype 1b (Con 1) backbone.15 Inhibition of HCV
RNA replication by either BMS-605339, BMS-788329 or
BMS-821095 for 72 h was monitored using a luciferase reporter
assay. Antiviral activities of the compounds, for example, the
50% inhibitory concentration (IC50), were determined as
described previously.16
Human serum samples
Human serum containing a high titre of HCV genotypes 1b, 2a
and 2b was obtained from patients with chronic hepatitis who
had given written informed consent to participate in the study.
Serum samples were divided into small aliquots and stored in
liquid nitrogen until use. The study protocol conforms to the
ethical guidelines of the 1975 Declaration of Helsinki and was
approved a priori by the institutional review committee.
Animal treatment
Generation of the uPA+/+/SCID+/+ mice and transplantation
of human hepatocytes were performed as described previ-
ously.17 All mice were transplanted with frozen human hepato-
cytes obtained from the same donor. All animal protocols
described in this study were performed in accordance with the
guidelines of the local committee for animal experiments, and
all animals received humane care. Infection, extraction of
serum samples and killing of animals were performed under
ether anaesthesia. Eight weeks after hepatocyte
transplantation, mice were injected intravenously with 100 ml
of HCV-positive human serum samples. Mice serum samples
were obtained every 1 or 2 weeks after HCV infection, and
HCV RNA levels were measured.
Treatment of HCV-infected mice with anti-HCV inhibitors
Eight weeks after HCV infection when the mice developed
stable viraemia (6–8 log10 copies/ml), mice were administered
orally with one of the following: 75 mg/kg of BMS-605339
(twice a day); 10 or 30 mg/kg of BMS-788329 (once a day); or
30 or 100 mg/kg of BMS-821095 (once a day) for 4 weeks. To
analyse the effect of the combination treatment, BMS-788329
was mixed with either BMS-605339 or BMS-821095 and given
together as a cocktail. To analyse susceptibility to Peg-alfa,
10 μg/kg of human Peg-alfa (Chugai Pharmaceutical Co. Ltd.,
Tokyo, Japan) were administered by intramuscular injection
twice a week for weeks.
RNA extraction and ampliﬁcation
RNA extraction, nested PCR and quantitation of HCV by real-
time PCR were performed as described previously.11 12 Brieﬂy,
RNA was extracted from serum samples and extracted livers
using SepaGene RVR (Sankojunyaku, Tokyo, Japan) and reverse
transcribed with a random hexamer and a reverse transcriptase
(ReverTraAce; TOYOBO, Osaka, Japan) according to the
instructions provided by the manufacturer. Quantitation of
HCV complementary DNA was performed using a light cycler
(Roche Diagnostic, Japan, Tokyo). The lower detection limit of
real-time PCR is 3 log10 copies/ml.
Sequence analysis
The nucleotide and amino acid sequences of the NS3, NS5A
and NS5B regions of HCV were determined by direct sequen-
cing as described previously.12 The primers used to amplify the
NS3 region were 50–GTGCTCCAAGCTGGCATAAC–30 and 50–
AGGACCGAGGAATCGAACAT–30 as the ﬁrst (outer) primer
pair and 50–CTAGAGTGCCGTACTTCGTG–30 and 50–ACTG
ATCCTGGAGGCGTAGC–30 as the second (inner) primer pair.
The primers used to amplify the NS5A region were 50–GAA
TGCAGCTCGCCGAGCAA–30 and 50–CCATGTTGTGGTGGC
GCAGC–30 as the ﬁrst (outer) primer pair and 50–GCAGCT
GTTGGCAGCATAGGTC–30 and 50–GATGGTAGTGCATGTCG
CC–30 as the second (inner) primer pair. The primers used to
amplify the NS5B region were 50–TAAGCGAGGAGGCTGG
TGAG–30 and 50–CCTATTGGCCTGGAGTGTTT–30 as the ﬁrst
(outer) primer pair and 50–GACTCAACGGTCACTGAGAG–30
and 50–CCTATTGGCCTGGAGTGTTT–30 as the second
(inner) primer pair. The ampliﬁed DNA fragments were sepa-
rated onto a 2% agarose gel and puriﬁed using the QIAquick
gel extraction kit (Qiagen, Hilden, Germany). Nucleotide
sequences were determined using BigDye Terminator v3.1 cycle
sequencing kit (Applied Biosystems Inc., California, USA). The
obtained nucleotide and amino acid sequences were compared
with the prototype sequences of genotype 1b HCV-J (GenBank
accession no.: D90208)18.
Ultra-deep sequencing
We have adapted multiplex sequencing by synthesis to
sequence multiple genomes simultaneously using the Illumina
genome analyser. Brieﬂy, cDNA was fragmented using sonic-
ation, and the resultant fragment distribution was assessed
using the Agilent BioAnalyzer 2100 platform. A library was
prepared using the Multiplexing sample preparation kit
(Illumina Inc., California, USA). Imaging analysis and base
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calling were performed using Illumina Pipeline software with
default settings. The N-terminal 1344 nucleotides of NS3 pro-
tease, 1146 nucleotides of NS5A RCI and 1133 nucleotides of
NS5B polymerase were analysed. This technique revealed an
average coverage depth of over 1000 sequence reads per base
pair in the unique regions of the genome. Read mapping to a
reference sequence was performed using BWA.19 Direct sequen-
cing consensus data were used to improve alignment to the ref-
erence sequence. Codon counts were merged and analysed
using R V.2.14.
Statistical analysis
Mice serum HCV RNA titres were compared using the Mann–
Whitney U test. A p value less than 0.05 was considered statis-
tically signiﬁcant.
RESULTS
Antiviral activities of BMS-605339, BMS-788329and
BMS-821095 in cell culture systems
The inhibitory effects of BMS-605339, BMS-788329 and
BMS-821095 on HCV replication were analysed in vitro using
HCV replicon cells (genotype 1b, Con 1 and genotype 2a,
JFH1). A summary of the IC50 values for each drug is shown in
table 1. Antiviral activities of BMS-605339 and BMS-788329
were similar to asunaprevir15 and daclatasvir,20 respectively.
BMS-605339 and BMS-821095 IC50 values were 23-fold and
116-fold more potent against genotype 1b than against geno-
type 2a, respectively.
Peg-alfa treatment on mice infected withHCV
genotypes 1 and 2
We ﬁrst analysed the effect of Peg-alfa on mice infected with
HCV genotypes 1 and 2. Mice were injected with 105 copies of
HCV obtained from patients infected with HCV genotypes 1b,
2a, or 2b. Administration of 10 μg/kg of human Peg-alfa twice a
week for 2 weeks resulted in only a 0.53 log10 decrease in the
serum HCV RNA titre in HCV genotype 1b-infected mice
(ﬁgure 1). In contrast, the same therapy resulted in 1.9 log10
and 1.5 log10 decreases in serum HCV RNA titres in mice with
HCV genotypes 2a (p<0.05) and 2b (not signiﬁcant), respect-
ively. No decline in HCV RNA titre was observed in control
mice infected with HCV genotype 1b during this 2-week
period (ﬁgure 1). These results are consistent with the clinical
observation that genotype 2 demonstrates a higher susceptibil-
ity to Peg-alfa treatment compared to HCV genotype 1.
Effects of BMS-605339, BMS-788329, or BMS-821095on HCV
genotype 1b in mice
We analysed the effect of DAA monotherapy on mice infected
with HCV genotype 1b. Nine mice were injected with 105
copies of HCV obtained from a patient infected with genotype
1b. Eight weeks after injection when stable viraemia had devel-
oped, mice were treated with BMS-605339 (N3PI) (ﬁgure 2A),
BMS-788329 (NS5A RCI) (ﬁgure 2B) or BMS-821095 (NS5B
site I inhibitor) (ﬁgure 2C) for 4 weeks. Although all
BMS-605339 and BMS-788329-treated mice showed an initial
reduction of serum HCV RNA titres, all later showed rebound
during treatment. Nucleotide analysis by direct sequencing
revealed the emergence of a mutation coding for D168E in the
NS3 region (NS3 PI-resistant variant)21 in a
BMS-605339-treated mouse (ﬁgure 2A), and a mutation coding
for Y93H in the NS5A region (NS5A RCI-resistant variant)14 in
a BMS-788329-treated mouse at week 4 of treatment (ﬁgure
2B). Almost all mice treated with BMS-821095 showed an
initial reduction in serum HCV RNA titres, and also showed
rebound with the emergence of mutations coding for P495A
and P495S in the NS5B region (NS5B site I inhibitor-resistant
variant)22 at week 4 of treatment (ﬁgure 2C). HCV RNA titre
reduction was not obvious in some mice treated with 30 mg/kg
of BMS-821095 (ﬁgure 2C), suggesting that exposure of this
inhibitor at 30 mg/kg dosing was not sufﬁcient to suppress
viral replication. Ultra-deep sequence analysis showed the
development of a high prevalence of drug-resistant variants in
mice sera in the NS3 PI, NS5A RCI-treated mice, and enrich-
ment of pre-existing resistance variants in the NS5B
NNI-treated mouse 4 weeks after the beginning of the treat-
ment (ﬁgure 2D).
Combination treatment of BMS-788329 with either
BMS-605339 or BMS-821095 in HCV genotype 1b mice
As monotherapies with either the NS3 PI, or the NS5A RCI or
the NS5B NNI were unable to eradicate HCV RNA due to the
emergent resistance variants, we analysed the effects of com-
bining the NS5A RCI with either the NS3 PI or NS5B NNI.
Mice infected with HCV genotype 1b (two mice per combin-
ation group) were treated with 10 mg/kg of BMS-788329 and
either 75 mg/kg twice daily of BMS-605339 or 100 mg/kg of
BMS-821095 for 4 weeks. In all mice, HCV RNA became nega-
tive by nested PCR 1 week after the beginning of combination
therapy and remained undetectable after cessation of treatment
(ﬁgure 3A,B). Elimination of the virus was assumed as HCV
RNA was undetectable by nested PCR in mice livers treated
with BMS-788329 and either BMS-605339 or BMS-821095
8 weeks (week 12) and 7 weeks (week 11) after cessation of
therapy, respectively (ﬁgure 3C).
Figure 1 Antiviral effects of Peg-alfa treatment in mice. Mice were
infected with hepatitis C virus (HCV) genotypes 1b (n=3), 2a (n=4) or
2b (n=4), then treated with 10 μg/kg of Peg-alfa twice per week for
2 weeks. HCV-infected mice without treatment (n=3) were also
analysed (control). Mice serum HCV RNA titres were measured at the
indicated times. Data are presented as mean±SD.
Table 1 In-vitro activity of BMS-605339, BMS-788329 and
BMS-821095 in HCV replicon assays
Genotype (strain)
IC50 (nM)
BMS-605339 BMS-788329 BMS-821095
1b (Con 1) 3.5±0.8 0.012±0.005 3.8±0.6
2a ( JFH-1) 81±27 0.014±0.007 365±266
Data are represented as means±SD from at least three independent experiments.
HCV, hepatitis C virus.##
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Combination treatment of BMS-788329 with either
BMS-605339 or BMS-821095 in HCV genotype 2 mice
We analysed the effect of DAA combination therapies on mice
infected with HCV genotypes 2a and 2b. In contrast to mice
with genotype 1b, mice with genotypes 2a or 2b failed to
respond to 4 weeks of treatment with BMS-788329 and
BMS-605339 (ﬁgure 4A,B). Although the combination of
BMS-788329 with BMS-821095 revealed no detectable viral
load decline at the time points examined in genotype 2a mice,
viral load reductions were detected in genotype 2b mice.
Sequence analysis revealed no emergence of resistance variants
in the NS3, NS5A or NS5B regions before and 4 weeks after the
end of each of these combination treatments, suggesting insuf-
ﬁcient drug selection pressure (data not shown).
DISCUSSION
DAA-only therapy may offer a promising option to eradicate
HCV without incurring the severe side effects of Peg-alfa.
However, the emergence of drug-resistant variants is expected
for all DAA21 and has already been observed in combination
Figure 2 Antiviral effects of BMS-605339, BMS-788329 or BMS-821095 monotherapy in mice infected with hepatitis C virus (HCV) genotype 1b.
Mice were injected intravenously with 105 copies of HCV genotype 1b. Eight weeks after HCV infection, mice were treated with the indicated
concentrations of BMS-605339 (A), BMS-788329 (B) or BMS-821095 (C) for 4 weeks. Serum samples were obtained at the indicated times, and
HCV RNA titre and nucleotide and amino acid (aa) sequences were analysed. HCV-infected mice without treatment were also analysed (control). The
horizontal dotted line indicates the HCV RNA titre detection limit (3 log copies/ml). (D) The aa frequencies in the BMS-605339 (top), BMS-788329
(middle bottom) or BMS-821095 (bottom) treated mice by ultra-deep sequencing before treatment and at 4 weeks are shown.
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therapies with two DAA.5 23 24 If the exposure of the drugs
can be safely increased, as we recently reported for a two-drug
combination administered to human hepatocyte chimeric
mice,12 eradication of virus is still possible. In this study, we
tested the ability of different two-DAA combination therapies
to eradicate HCV. Although DAA monotherapies resulted in a
viral breakthrough due to the development of a high prevalence
of drug-resistant variants (ﬁgure 2A–D), DAA combination
therapies with the NS5A RCI and either the NS3 PI or NS5B
NNI were shown to eradicate virus successfully from HCV
genotype 1b-infected mice with only 4 weeks of treatment
(ﬁgure 3). These two-DAA combination treatments resulted in
more rapid, robust declines within the ﬁrst week of treatment
when compared with the suboptimal antiviral responses from
each of their respective monotherapies. Furthermore, regimens
containing NS5A RCI appeared equally effective in treating
mice chronically infected with hepatitis C genotype 1b.
In contrast to the rapid decrease in HCV RNA in mice
infected with HCV genotype 1b, HCV genotype 2a and
2b-infected mice either did not respond or responded poorly to
treatment with the NS5A RCI combined with either the NS3
PI or NS5B NNI (ﬁgure 4A,B). In this study, NS3 PI and NS5B
NNI IC50 values against genotype 1b were markedly more
potent than against genotype 2a in cell culture systems (table 1).
These ﬁndings are consistent with previous experimental
results that reported reduced activity of these drug classes
against genotype 2.25–28 In clinical trials, telaprevir monother-
apy was found to result in a rapid decrease in serum HCV
RNA levels in patients infected with HCV genotype 2;
however, another protease inhibitor, BILN-2061, was less effect-
ive in patients with HCV genotype 2 compared to genotype
1.29 Sequence analysis revealed a pre-existing A156G variant in
the NS3 region, a L31M variant in the NS5A region and a
I482L variant in the NS5B region in both HCV genotypes 2a
and 2b infecting strains used in this study (data not shown).
These NS3-A156G and NS5A-L31M variants confer resistance
to inhibitors with similar chemical structures to BMS-605339
and BMS-788329, respectively, in genotype 2a replicon cell
culture assays.30–32 Although BMS-788329 was very potent
against the genotype-2a JFH-1 replicon (IC50 0.014 nM; table
1), its activity was signiﬁcantly less against other genotype 2a
and 2b viruses, such as genotype 2a HC-J6CF. The loss in
potency observed in these viruses is not surprising because
these viruses have a methionine at NS5A amino acid residue
31. The IC50 of a genotype 2a hybrid replicon containing
HC-J6CF NS5A with L31M substitution is approximately
10 nM (data not shown). The minimal antiviral response in
mice infected with genotypes 2a and 2b receiving treatments
containing BMS-788329 with either BMS-605339 or
BMS-821095 can therefore be explained by pre-existing NS3,
NS5A and NS5B resistance variants. Nevertheless, it is possible
that mice infected with wild-type genotype 2 viruses and sub-
sequently treated with higher doses of each of these DAA in
dual or even triple combination therapy may have resulted in
more robust reductions in viral load. The human hepatocyte
chimeric mouse model offers a viable approach for identifying
effective DAA-only combinations that not only act against
HCV genotype 1 but against all HCV genotypes.
In summary, we demonstrated that an NS5A RCI can be
effectively combined with different inhibitor classes to cure
human hepatocyte chimeric mice infected with HCV genotype
1b after 4 weeks of treatment. However, these treatment com-
binations were not effective against HCV genotype 2. Oral
combinations incorporating an NS5A RCI might offer
Peg-alfa-free treatment options for genotype 1b chronic hepa-
titis C patients.
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Figure 3 Antiviral effects of NS5A replication complex inhibitor
combinations with either an NS3 protease inhibitor or an NS5B inhibitor
in mice infected with hepatitis C virus (HCV) genotype 1b. The four
mice were treated with 10 mg/kg of BMS-788329 and either 75 mg/kg
twice daily of BMS-605339 (A) or 100 mg/kg of BMS-821095 (B) for
4 weeks (closed circles). Mice without treatment were also analysed
(open circles). Serum samples were obtained at the indicated times,
and HCV RNA titres were measured. The horizontal dotted line
indicates the HCV RNA titre detection limit (3 log copies/ml). (C)
Nested PCR of HCV RNA, human serum albumin and GAPDH in mouse
livers. Livers from mice treated with BMS-788329 and either
BMS-605339 (lane 2) or BMS-821095 (lane 3) were obtained. Mouse
livers with (lane 1) or without (lane 4) HCV infection were also
analysed.
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